医学
伊布替尼
专家意见
重症监护医学
微小残留病
慢性淋巴细胞白血病
内科学
白血病
作者
Michael Hallek,Bruce D. Cheson,Daniel Catovsky,Federico Caligaris‐Cappio,Guillermo Dighiero,Hartmut Döhner,Peter Hillmen,Michael J. Keating,Emili Montserrat,Nicholas Chiorazzi,Stephan Stilgenbauer,R. Kanti,John C. Byrd,Barbara Eichhorst,Susan O’Brien,Tadeusz Robak,John F. Seymour,Thomas J. Kipps
出处
期刊:Blood
[Elsevier BV]
日期:2018-03-14
卷期号:131 (25): 2745-2760
被引量:1401
标识
DOI:10.1182/blood-2017-09-806398
摘要
Abstract The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion–based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.
科研通智能强力驱动
Strongly Powered by AbleSci AI